UY38657A - Derivados de carbamoil-ciclohexano para tratar el trastorno del espectro del autismo - Google Patents
Derivados de carbamoil-ciclohexano para tratar el trastorno del espectro del autismoInfo
- Publication number
- UY38657A UY38657A UY0001038657A UY38657A UY38657A UY 38657 A UY38657 A UY 38657A UY 0001038657 A UY0001038657 A UY 0001038657A UY 38657 A UY38657 A UY 38657A UY 38657 A UY38657 A UY 38657A
- Authority
- UY
- Uruguay
- Prior art keywords
- disorder
- autism spectrum
- carbamoil
- derivatives
- autism
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 4
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 abstract 3
- 201000007197 atypical autism Diseases 0.000 abstract 2
- 229960005123 cariprazine Drugs 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 230000001953 sensory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al compuesto de trans-N-[4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclohexil]-N’,N’-dimetilurea (cariprazina), sus sales, análogos cercanos, derivados, composiciones farmacéuticas, metabolitos y combinaciones para su uso en el tratamiento de los síntomas del trastorno del espectro autista en general, y preferentemente el objeto de la presente invención es tratar uno o más síntomas del autismo. Además, se determi nó también que la cariprazina, sus sales, análogos cercanos, derivados, composiciones farmacéuticas, metabolitos y combinaciones son adecuadas para el tratamiento de afecciones tales como el síndrome de Asperger, autismo atípico (también conocido como trastorno generalizado del desarrollo no especificado de otra manera, TGD NE), el síndrome de Rett, el trastorno desintegrativo de la infancia, el trastorno por el déficit de atención e hiperactividad (TDAH) y la disfunción de integración sensorial
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1900121A HU231500B1 (hu) | 2019-04-10 | 2019-04-10 | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38657A true UY38657A (es) | 2020-10-30 |
Family
ID=89992883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038657A UY38657A (es) | 2019-04-10 | 2020-04-13 | Derivados de carbamoil-ciclohexano para tratar el trastorno del espectro del autismo |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP3952872B1 (es) |
| JP (1) | JP2022527386A (es) |
| KR (1) | KR20210151162A (es) |
| CN (1) | CN113677345A (es) |
| AR (1) | AR118634A1 (es) |
| AU (1) | AU2020271363A1 (es) |
| BR (1) | BR112021019367A2 (es) |
| CL (1) | CL2021002632A1 (es) |
| DK (1) | DK3952872T3 (es) |
| EA (1) | EA202192717A1 (es) |
| FI (1) | FI3952872T3 (es) |
| GE (1) | GEP20237554B (es) |
| HR (1) | HRP20240772T1 (es) |
| HU (1) | HU231500B1 (es) |
| IL (1) | IL287076A (es) |
| LT (1) | LT3952872T (es) |
| MX (1) | MX2021012321A (es) |
| PL (1) | PL3952872T3 (es) |
| PT (1) | PT3952872T (es) |
| RS (1) | RS65530B1 (es) |
| SG (1) | SG11202110421YA (es) |
| SI (1) | SI3952872T1 (es) |
| TW (1) | TW202103701A (es) |
| UY (1) | UY38657A (es) |
| WO (1) | WO2020208564A1 (es) |
| ZA (1) | ZA202108429B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588162B (zh) * | 2022-03-30 | 2023-10-27 | 中国人民解放军空军军医大学 | 拉莫三嗪治疗孤独症触觉异常的应用 |
| US11980603B2 (en) | 2022-06-11 | 2024-05-14 | AMS Therapeutics, LLC | Method of treating expressive language deficit in autistic humans |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| KR20150023937A (ko) | 2007-05-11 | 2015-03-05 | 리히터 게데온 닐트. | 카르바모일-사이클로헥산 유도체의 신규한 용매화물 및 결정 형태 |
| HU230748B1 (hu) | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
| HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| MY157192A (en) * | 2007-08-03 | 2016-05-13 | Richter Gedeon Nyrt | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| PL2317852T3 (pl) | 2008-07-16 | 2015-05-29 | Richter Gedeon Nyrt | Preparaty farmaceutyczne zawierające ligandy receptora dopaminy |
| WO2011060363A2 (en) | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| RS56931B1 (sr) | 2013-12-13 | 2018-05-31 | Pf Medicament | Hromonski derivat kao antagonist dopaminskog d3 receptora za upotrebu u lečenju poremećaja autističnog spektra |
-
2019
- 2019-04-10 HU HUP1900121A patent/HU231500B1/hu unknown
-
2020
- 2020-03-11 TW TW109108018A patent/TW202103701A/zh unknown
- 2020-04-08 AR ARP200101001A patent/AR118634A1/es unknown
- 2020-04-09 GE GEAP202015793A patent/GEP20237554B/en unknown
- 2020-04-09 PT PT207197377T patent/PT3952872T/pt unknown
- 2020-04-09 BR BR112021019367A patent/BR112021019367A2/pt unknown
- 2020-04-09 SI SI202030436T patent/SI3952872T1/sl unknown
- 2020-04-09 SG SG11202110421YA patent/SG11202110421YA/en unknown
- 2020-04-09 WO PCT/IB2020/053382 patent/WO2020208564A1/en active Application Filing
- 2020-04-09 EP EP20719737.7A patent/EP3952872B1/en active Active
- 2020-04-09 JP JP2021559605A patent/JP2022527386A/ja active Pending
- 2020-04-09 AU AU2020271363A patent/AU2020271363A1/en active Pending
- 2020-04-09 KR KR1020217036553A patent/KR20210151162A/ko active Search and Examination
- 2020-04-09 DK DK20719737.7T patent/DK3952872T3/da active
- 2020-04-09 HR HRP20240772TT patent/HRP20240772T1/hr unknown
- 2020-04-09 PL PL20719737.7T patent/PL3952872T3/pl unknown
- 2020-04-09 LT LTEPPCT/IB2020/053382T patent/LT3952872T/lt unknown
- 2020-04-09 MX MX2021012321A patent/MX2021012321A/es unknown
- 2020-04-09 RS RS20240573A patent/RS65530B1/sr unknown
- 2020-04-09 EA EA202192717A patent/EA202192717A1/ru unknown
- 2020-04-09 FI FIEP20719737.7T patent/FI3952872T3/fi active
- 2020-04-09 CN CN202080027793.XA patent/CN113677345A/zh active Pending
- 2020-04-13 UY UY0001038657A patent/UY38657A/es unknown
-
2021
- 2021-10-07 IL IL287076A patent/IL287076A/en unknown
- 2021-10-08 CL CL2021002632A patent/CL2021002632A1/es unknown
- 2021-10-29 ZA ZA2021/08429A patent/ZA202108429B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS65530B1 (sr) | 2024-06-28 |
| ZA202108429B (en) | 2022-09-28 |
| IL287076A (en) | 2021-12-01 |
| HU231500B1 (hu) | 2024-04-28 |
| PL3952872T3 (pl) | 2024-07-22 |
| GEP20237554B (en) | 2023-10-25 |
| DK3952872T3 (da) | 2024-05-27 |
| SI3952872T1 (sl) | 2024-07-31 |
| HUP1900121A1 (hu) | 2020-10-28 |
| EP3952872B1 (en) | 2024-03-13 |
| CN113677345A (zh) | 2021-11-19 |
| AU2020271363A1 (en) | 2021-11-18 |
| CL2021002632A1 (es) | 2022-05-06 |
| FI3952872T3 (fi) | 2024-06-12 |
| KR20210151162A (ko) | 2021-12-13 |
| EP3952872A1 (en) | 2022-02-16 |
| HRP20240772T1 (hr) | 2024-09-13 |
| PT3952872T (pt) | 2024-05-22 |
| BR112021019367A2 (pt) | 2021-12-07 |
| MX2021012321A (es) | 2021-11-12 |
| JP2022527386A (ja) | 2022-06-01 |
| EA202192717A1 (ru) | 2022-01-17 |
| TW202103701A (zh) | 2021-02-01 |
| AR118634A1 (es) | 2021-10-20 |
| SG11202110421YA (en) | 2021-10-28 |
| LT3952872T (lt) | 2024-05-27 |
| WO2020208564A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002632A1 (es) | Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| CL2019001264A1 (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| CO2020005459A2 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
| ECSP21091615A (es) | Derivados de benzisoxazol sulfonamida | |
| CU20110168A7 (es) | Derivados de benzofuranilo | |
| CL2011000306A1 (es) | Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion. | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| CL2012001461A1 (es) | Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras. | |
| ECSP12011857A (es) | Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso | |
| CR20130580A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| ECSP19020742A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| CO2020005486A2 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x | |
| CL2011002617A1 (es) | Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros. | |
| UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
| CL2021000424A1 (es) | Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección | |
| BR112018004719A2 (pt) | composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto | |
| CL2012000013A1 (es) | Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer. | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| BR112015000392A2 (pt) | novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório |